News
Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...
Titer tests are what's used "to help you determine if you currently have immunity to certain diseases due to past infection ...
Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...
Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...
Quest Diagnostics to offer US FDA-approved Fujirebio blood test for Alzheimer's disease: Secaucus, New Jersey Friday, July 11, 2025, 14:00 Hrs [IST] Quest Diagnostics, a leader in ...
Plasma proteomics reveals that the biological ages of key organs, especially the brain and immune system, strongly predict ...
Researchers are making ever more sophisticated mini organs in the lab — and now they can grow their own blood vessels. The ...
Berkeley scientists have developed a smartphone-based biosensor that mimics coffee-ring physics to detect disease proteins ...
This test complements Fujirebio’s growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company’s leading position in advancing neuro biomarker research ...
Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results